Watch "An Update on the Clinical Studies Using Arimoclomol as a Potential Treatment for sIBM" with Dr. Mazen Dimachkie,...
Tag Archive for: inclusion body myositis
RDMD and MSU Collaborating for IBM Research
Myositis Support, , Featured, Inclusion Body Myositis (IBM), NewsWe are excited to announce a new collaboration with RDMD, a company that aims to jumpstart research for patients...
During Myositis Awareness Month, May 2018, we placed a large focus on patient education by hosting some of the...
EULAR/ACR Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies and Their Major Subgroups
Myositis Support, , Featured, NewsClinical trials and studies require patient groups in clearly defined categories, but the multiple diagnostic and classification criteria used...
Advances in the Early Diagnosis and Therapy of Inclusion Body Myositis
Myositis Support, , Featured, Inclusion Body Myositis (IBM)The purpose of this article is to describe advancements in the diagnosis of Inclusion Body Myositis (IBM) and therapy...
MSU and Orphazyme: Working together for a treatment for inclusion body myositis
Myositis Support, , Featured, NewsUpdated April 23, 2019 - Study is fully enrolled. One of our goals is to provide inclusion body...
New Study for Patients with Inclusion Body Myositis (IBM) at Yale
Myositis Support, , Inclusion Body Myositis (IBM)We would like to let you know about a clinical research study that is available for patients diagnosed with...
New Insights on sporadic Inclusion body myositis (sIBM) pathogenesis
Myositis Support, , Inclusion Body Myositis (IBM), News, VideoDr. Conrad "Chris" Weihl joins MSU live for a session titled "New Insights on sporadic Inclusion body myositis (sIBM)...
The NT5C1A Antibody Test and its Role in the Diagnosis of Inclusion Body Myositis
Myositis Support, , Inclusion Body Myositis (IBM), VideoLearn more about the NT5CIA antibody and its association with inclusion body myositis from Dr. Kevin Dooley, a retired...
Orphazyme formally assumes the sponsorship of Phase II/III arimoclomol trial for sIBM
Myositis Support, , Inclusion Body Myositis (IBM), NewsOn December 14, 2017, Orphazyme A/S, University of Kansas Medical Center, and UCL announced that Orphazyme formally assumes the...
A touching personal story from the daugher of a myositis patient remembering that her Dad, her longtime hero, ...
FDA grants Orphazyme drug arimoclomol orphan drug designation in the U.S.
Myositis Support, , Inclusion Body Myositis (IBM), NewsOrphazyme A/S, a Danish biotech company with a late-stage orphan drug pipeline, today announced that the U.S. Food and...
Sadly, my mum lost her battle as an IBM warrior
Myositis Support, , Inclusion Body Myositis (IBM), Personal StoriesMums journey was a very difficult one. I remember her first fall the day I gave birth to...
Maureen Hume shares her experiences living with Inclusion Body Myositis, staring years before her diagnosis.